VISTIN PHARMA ASA

Vistin Pharma ASA is listed on Euronext Oslo, so its shareholder information reflects disclosure of significant holdings rather than a complete private-company shareholder register. Registry-linked shareholder data verified as at 2 August 2026 lists total shares outstanding of 44,344,592 and identifies four named holders: Intertrade Shipping AS (28.36%, 12,575,000 shares), Holmen Spesialfond (9.47%, 4,200,379 shares), Pactum Vekst AS (6.75%, 2,991,773 shares) and MP Pensjon PK (3.88%, 1,719,848 shares). The remaining 51.55% (22,857,592 shares) is recorded under an aggregated “other shareholders” category rather than broken down to individual holders at this level of the record.

The company’s own investor communications, in a shareholder overview referencing 30 June 2026, separately describe Intertrade Shipping AS as the largest shareholder with a stake of approximately 32.70% of the same total share count. The two figures differ because they are snapshots taken roughly a month apart, and Intertrade Shipping AS’s holding should be treated as a position that moves over time rather than a fixed percentage.

Ultimate beneficial ownership: no source reviewed traces the ownership of Intertrade Shipping AS, Holmen Spesialfond, Pactum Vekst AS or MP Pensjon PK back to a natural person, so no verified Ultimate Beneficial Owner is identified at this level.

Data availability: Major shareholders only. Norwegian flagging obligations and Euronext Oslo disclosure rules require reporting of significant holdings and changes to them, but the complete shareholder base below the disclosure threshold is not separately published. (Sources: registry-linked shareholder data, verified 2 August 2026; Vistin Pharma ASA investor relations shareholder overview, referencing 30 June 2026, vistin.com.)

Current role filings with the Norwegian Register of Business Enterprises (Brønnøysundregistrene), checked in September 2026, record the following active appointments for Vistin Pharma ASA: Magnus Wilhelm Tolleshaug as daglig leder (chief executive officer); Øyvin Anders Brøymer as styrets leder (chairman of the board); board members (styremedlemmer) Kari Eian Krogstad, Espen Weyergang Marcussen, Bettina Banoun, Stine Wang Rønningen and Espen Lia Gregoriussen; deputy board members (varamedlemmer) Arve Kristensen, Kristine Pedersen, Guro Amalie Øyløkken and Stig Isaksen; and Ernst & Young AS as registered auditor. None of these role records carry a resignation date.

The company’s own corporate-governance page additionally names an executive management team beyond the registered daglig leder role: Magnus Tolleshaug as Chief Executive Officer (in the role since 1 January 2024, with the company since March 2020), Alexander Karlsen as Chief Financial Officer (with the company since March 2020), Vegard Heggem as Chief Operating Officer / Vice President Operations, and Lilly Margareth Myra as Vice President Quality & Regulatory Affairs, plus a named board observer, Kjell-Erik Nordby, who does not appear in the formal Brønnøysundregistrene role filing.

Recent officer changes: this profile’s previously recorded registry-linked officer data included an individual, Øystein Spetalen, as an active board member; that person is not present in the current Brønnøysundregistrene role filing checked for this update, indicating the earlier record was outdated. No effective date for that change could be confirmed from the sources reviewed.

Data availability: Current only, sourced from the Norwegian company register, which publishes role, appointment status and (where recorded) date of birth, but does not disclose nationality; nationality is therefore not stated for any individual above and has not been inferred from name or residence. Correspondence addresses on file are registry service addresses, not home addresses. (Sources: data.brreg.no roller register, checked September 2026; Vistin Pharma ASA corporate governance and about-us pages, vistin.com.)

Vistin Pharma ASA is the top entity in its own registry-linked corporate structure rather than a subsidiary of another identified corporate parent: no single shareholder holds a majority stake, and no controlling parent company is disclosed in the sources reviewed, so the group’s ultimate parent is Vistin Pharma ASA itself.

Registry-linked corporate-linkage data identifies one direct operating subsidiary, Vistin Pharma AS (Norway, registration number 813120232), confirmed as active with Brønnøysundregistrene and sharing Vistin Pharma ASA’s Østensjøveien 27, Oslo business address, though Vistin Pharma AS’s own register entry does not flag itself as part of a registered “konsern” (group-accounts) filing. Below that, the same data identifies two further entities as indirect subsidiaries: Vistin Pharma in Sweden (registration number SE 5020759873) and Vistin Pharma Korlátolt Felelősségű Társaság in Hungary (registration number HU 27511431241). Ownership percentages for these relationships are not disclosed in the sources reviewed, so full or partial ownership cannot be confirmed; they should be read as operating/sales entities linked to the Norwegian parent rather than as verified wholly-owned subsidiaries.

Vistin Pharma ASA’s own published material (annual reports, corporate governance and about-us pages) was checked for this update but did not itself name the Swedish or Hungarian entities, so that part of the structure rests on the registry-linked corporate-linkage data alone and has not been independently corroborated from the company’s own annual report within this review.

Data availability: Subsidiaries only, and partial even at that level: the direct and indirect subsidiaries are identified, but ownership and voting percentages are not disclosed, and the Swedish and Hungarian entities are not independently confirmed by the parent’s own public materials. (Sources: registry-linked corporate-linkage data; data.brreg.no entity lookups for organisation numbers 915157882 and 813120232, checked September 2026; vistin.com about-us page.)